Abstract
In recent years, the use of cellular immunotherapies has become widespread for the treatment of patients with refractory malignancies. While this has led to improved overall outcomes, these therapies have been associated with numerous, sometimes severe cardiotoxicities. In this review, we highlight the spectrum of cardiovascular adverse events that can occur following cellular immunotherapies with a particular emphasis on the pre-treatment risk factors that may be associated with these cardiotoxicities.